High TCTA expression is an adverse prognostic biomarker in acute myeloid leukemia
Year: 2024
Type: article
Abstract: Background Acute myeloid leukemia (AML) prognosis varies greatly, underscoring the need for novel biomarkers to improve patient stratification. T-cell leukemia translocation-associated gene (TCTA) has emerged as a potential player in hematological malignancies, yet its role in AML remains unexplored. Objective To investigate the prognostic significance of TCTA in AML and elucidate its functional mechanisms. Methods RNA sequencing data from 173 AML patients (TCGA) and 70 normal controls (GTEx) were analyzed. Patients were categorized into high and low TCTA expression groups. Bioinformatics tools assessed Gene Ontology, KEGG pathways, and immune infiltration and constructed a nomogram predicting 1–5-year overall survival (OS). Results High TCTA expression correlated with significantly reduced OS ( P < 0.001), with multivariate analysis identifying TCTA expression alongside age and cytogenetic risk as independent OS predictors. Receiver operating characteristic analysis validated TCTA's diagnostic potential. Enrichment analyses implicated TCTA in pathways critical to AML, such as hematopoiesis, p53 signaling, and DNA methylation, with a notable association with natural killer (NK) cell activity. Conclusions Elevated TCTA expression signifies poor prognosis in AML, positioning it as a promising prognostic biomarker. Its involvement in key AML-related pathways highlights TCTA's functional relevance and potential as a therapeutic target in AML management.
Source: Cancer Biomarkers
Authors: Yunli Shao, Tong Qin
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4407157092